Mai 18th, 2012 by blandos
|
Pradaxa – A Misfire?
InjuryBoard.com The problem with dabigatran is that it has been presented as a "fire-and-forget" medicine. That is, the doctor can write a prescription and not think about it again. But anticoagulation is not like that. Just because patients on dabigatran don't need … |
Mai 14th, 2012 by blandos
|
Pradaxa More Dangerous than Warfarin
CisionWire (press release) Dr. Mark Wurster and his colleagues analyzed the clinical records of 113 patients who had switched their treatment plan from warfarin to dabigatran – the active drug in Pradaxa. Patients who were analyzed took the drug for a mean time of nearly four … |
Mai 8th, 2012 by blandos
 Drug Alert |
Researcher's Real-World Study Claims Pradaxa Riskier than Warfarin
Drug Alert According to preliminary results from an ongoing study comparing the new blood thinner Pradaxa (dabigatran) to warfarin, complications required patients to stop using the new medication far more frequently than the older one. Both Pradaxa and warfarin … Weighing the risks of Pradaxa vs. the risk of stroke |
Mai 7th, 2012 by blandos
|
Weighing the risks of Pradaxa vs. the risk of stroke
MedCity News The novel blood thinning drug for patients with atrial fibrillation, Dabigatran (Pradaxa) cannot get a break. It's all over the TV: Pradaxa = Bad Drug. Today, on the prestigious heart news site, theHeart.org, an insignificant 113-patient study … More adverse events seen on dabigatran vs warfarin |
Mai 2nd, 2012 by blandos
 Drug Alert |
Patients Taking Anticoagulant Pradaxa Face Bleeding Death, Heart Attack Concerns
Drug Alert In December, the US Food and Drug Administration (FDA) released a safety announcement explaining they were evaluating “post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). |
April 27th, 2012 by blandos
|
Lower rates of intracranial hemorrhage seen with Pradaxa
ModernMedicine Twice-daily dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim) was shown to be associated with lower rates of fatal and traumatic intracranial hemorrhage (ICH) compared with warfarin, according to the results of a retrospective subanalysis … |
April 24th, 2012 by blandos
|
Pradaxa sales give Boehringer a lift
Cardiovascular Business Buoyed by sales of its anticoagulant drug dabigatran (Pradaxa), Boehringer Ingelheim recorded a 6.2 percent increase in net sales for the fiscal year 2011, the pharmaceutical company reported. Net sales totaled EUR13.2 billion ($ 17.4 billion US), … |
April 20th, 2012 by blandos
|
Pradaxa associated with significantly lower rates of fatal and traumatic …
pharmabiz.com A new analysis of the 18113 patient, RE-LY trial highlights significantly lower rates of both fatal and traumatic intracranial haemorrhage (ICH) in patients treated with dabigatran etexilate (Pradaxa) 110mg and 150mg bid compared to those treated with … New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial … |
April 18th, 2012 by blandos
|
Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of …
EON: Enhanced Online News (press release) INGELHEIM, Germany–(EON: Enhanced Online News)–A new analysis of the 18113 patient, RE-LY ® trial highlights significantly lower rates of both fatal and traumatic intracranial haemorrhage (ICH) in patients treated with dabigatran etexilate (Pradaxa … New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial … |
April 7th, 2012 by blandos
|
Pradaxa Overdose and Hemorrhages Report
InjuryBoard.com Pradaxa (dabigatran) is associated with more adverse reported cases than any other regularly monitored drug, the anticoagulant had been on the market for less than a year at the time. Pradaxa was associated with 856 reports of serious, disabling or … |